|
||||||
|
 | |
| |
| Expression of this gene in the resistant group across all datasets and cell types |
| Significant ligand-receptor pairs related to this gene (This gene does not contain this module) |
| |
| |
| |
| Acts as a transcription factor (This gene does not contain this module) |
|
Gene: TP53 |
Summary for TP53 |
| Gene information | Gene symbol | TP53 | Ensembl ID | ENSG00000141510 |
| Entrez ID | 7157 | |
| Gene name | tumor protein p53 | |
| Synonyms | LFS1|p53 | |
| Gene type | protein_coding | |
| UniProtAcc | NA |
Top |
Dataset with differentially expressed gene: TP53 |
 Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group. |
| Dataset | Source | Tissue | Cancer type level1 | Cancer type level2 | Drug type | Regimen | Timepoint | Cell type | avg_log2FC | p_val_adj |
GSE186960 | Panc1 cell line | Cell line | Pancreatic cancer | Pancreatic ductal adenocarcinoma (PDAC) | Chemotherapy | gemcitabine | NA | Malignant cells | 0.68634 | 0.00e+00 |
GSE138267 | CDX | Tumor tissue | Lung cancer | Small cell lung cancer (SCLC) | Chemotherapy | NA | NA | Malignant cells | 0.266388 | 0.00e+00 |
GSE199333 | patients | Bone marrow aspirate | Acute myeloid leukemia | Primary FLT3-ITD-mutated acute myeloid leukemia (AML) | Targeted therapy | gilteritinib | post | Malignant cells | 0.253305 | 0.00e+00 |
Top |
Expression of TP53 in the resistant group across all datasets and cell types |
| Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.) |
 |
Top |
Significant ligand-receptor pairs related to TP53 |
| This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.) |
Top |
Known drug resistance mechanisms of this gene |
| This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information. |
| Gene symbol | Mechanism |
TP53 | Aberration of the Drug's Therapeutic Target |
TP53 | Epigenetic Alteration of DNA, RNA or Protein |
TP53 | Unusual Activation of Pro-survival Pathway |
| Page: 1 |
Top |
MicroRNAs (miRNA) regulating TP53 |
| This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.) |
| Gene symbol | miRNA | Score | GeneBank accession |
| TP53 | hsa-miR-3922-5p | 95.2545 | NM_001276698 |
| TP53 | hsa-miR-381-3p | 88.9186 | NM_001276761 |
| TP53 | hsa-miR-300 | 88.9186 | NM_001276761 |
| TP53 | hsa-miR-5701 | 86.0579 | NM_001276698 |
| TP53 | hsa-miR-4284 | 83.1479 | NM_001276761 |
| TP53 | hsa-miR-6842-3p | 81.6432 | NM_001276698 |
| TP53 | hsa-miR-491-5p | 81.4239 | NM_001276761 |
| Page: 1 |
Top |
Motifs and transcription factors (TFs) regulating TP53 |
| This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.) |
| Gene symbol | motif | TF_highConf |
| TP53 | jaspar__MA1933.1 | SREBF2 (directAnnotation). |
| TP53 | taipale_tf_pairs__ETS2_RCCGGAAGTG_HT | ETS2 (directAnnotation). |
| TP53 | metacluster_34.4 | ETS1; ETS1; ETS1; HCFC1; SIX5; SIX5; SIX5; SIX5; SMARCC2; SMARCC2; THAP11; THAP11; ZNF143; ZNF143; ZNF143; ZNF143 (directAnnotation). TBX2; THAP11; THAP11; ZNF143 (inferredBy_Orthology). |
| TP53 | jaspar__MA1483.2 | ELF2 (directAnnotation). |
| TP53 | metacluster_191.3 | EHF; ELF1; ELF1; ELF1; ELF4; ELK1; ELK3; ELK3; ELK4; ELK4; ERF; ETS1; ETS2; ETV3; ETV4; ETV5; FEV; FEV; FLI1; FLI1; GABPA; GABPA; GABPA; GABPA; GABPA; GABPA; SPDEF; ZNF200 (directAnnotation). ELK1; ELK1; ELK3; ELK3; ELK4; ELK4; ETV1; ETV1; ETV4; ETV4; ETV4; ETV5; GABPA; GABPA (inferredBy_Orthology). |
| TP53 | swissregulon__hs__ELF2 | ELF2 (directAnnotation). |
| TP53 | taipale_tf_pairs__ELK1_FOXI1_RSCGGATGTKKN_CAP | ELK1; FOXI1 (directAnnotation). |
| TP53 | taipale_tf_pairs__ETV2_FOXO6_RCCGGATGTTKWN_CAP | ETV2; FOXO6 (directAnnotation). |
| TP53 | taipale_tf_pairs__HOXB2_ETV4_ACCGGAAATGAN_CAP | ETV4; HOXB2 (directAnnotation). |
| TP53 | metacluster_166.4 | BCLAF1; EHF; ELF1; ELF1; ELF1; ELF1; ELF1; ELF1; ELF2; ELF2; ELF4; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK3; ELK3; ELK3; ELK3; ELK4; ERG; ERG; ERG; ERG; ETS1; ETS1; ETS1; ETS1; ETS1; ETV1; ETV1; ETV1; ETV1; ETV2; ETV3; ETV4; ETV4; ETV4; ETV4; ETV4; ETV5; ETV7; FEV; FEV; FLI1; FLI1; FLI1; FLI1; GABPA; GABPA; GABPA; GABPA; GABPA; GABPA; GABPB1; GATAD1; PHF20; ZBTB25; ZBTB40 (directAnnotation). EHF; ELF1; ELF1; ELF3; ELF5; ELK3; ELK4; ERG; ETS1; ETV1; ETV2; ETV4; FLI1; GABPA; GABPA (inferredBy_Orthology). |
| TP53 | taipale_tf_pairs__ETV5_FOXI1_RSCGGATGTTGN_CAP | ETV5; FOXI1 (directAnnotation). |
| TP53 | taipale_tf_pairs__ERF_FOXI1_RSCGGATGTTKWN_CAP_repr | ERF; FOXI1 (directAnnotation). |
| TP53 | hdpi__TP73 | TP73 (directAnnotation). |
| TP53 | metacluster_34.3 | EGR1; ETS1; SETDB1; SIX5; SIX5; ZNF143; ZNF76 (directAnnotation). |
| TP53 | taipale_tf_pairs__ETV2_FOXI1_RSCGGATGTTKW_CAP | ETV2; FOXI1 (directAnnotation). |
| TP53 | transfac_pro__M04748 | GABPA (directAnnotation). |
| TP53 | taipale_tf_pairs__FOXO1_ELK1_RSCGGATGTTRTN_CAP | ELK1; FOXO1 (directAnnotation). |
| TP53 | taipale_tf_pairs__FOXO1_ELK3_RCCGGAWGTKKW_CAP | ELK3; FOXO1 (directAnnotation). |
| TP53 | taipale_tf_pairs__TEAD4_ERG_RSCGGAAATRCC_CAP | ERG; TEAD4 (directAnnotation). |
| TP53 | taipale_tf_pairs__TEAD4_ERG_RSCGGAAATRCC_CAP_repr | ERG; TEAD4 (directAnnotation). |
| TP53 | taipale_tf_pairs__HOXB2_ETV1_ACCGGAAATGA_CAP | ETV1; HOXB2 (directAnnotation). |
| Page: 1 |
Top |
Acts as a transcription factor |
| This table shows that this differential gene acts as a transcription factor. |
Top |
Acts as a drug target |
| This table shows that this differential gene acts as a drug target. |
| Target name | Drug name | Drug ID | Drug type |
| TP53 | "1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine" | DB08363 | small molecule |
| TP53 | "Acetylsalicylic acid" | DB00945 | small molecule |
| TP53 | "AZD 3355" | DB05404 | small molecule |
| TP53 | "Triethyl phosphate" | DB03347 | small molecule |
| TP53 | "Zinc acetate" | DB14487 | small molecule |
| TP53 | "Zinc chloride" | DB14533 | small molecule |
| TP53 | "Zinc sulfate, unspecified form" | DB14548 | small molecule |
| TP53 | "Zinc" | DB01593 | small molecule |
| Page: 1 |
| 1 | "Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618." |
| 2 | "Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335." |
| 1 | "Longitudinal copy number, whole exome and targeted deep sequencing of 'good risk' IGHV-mutated CLL patients with progressive disease" |
| 2 | Carboplatin-docetaxel-induced activity against ovarian cancer is dependent on up-regulated lncRNA PVT1 |
| 3 | Has miR 125a and 125b are induced by treatment with cisplatin in nasopharyngeal carcinoma and inhibit apoptosis in a p53 dependent manner by targeting p53 mRNA |
| 4 | Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/Beta-catenin signaling pathway |
| 5 | Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA |
Copyright 2022-Present -The University of Texas Health Science Center at Houston |